Patents Assigned to Millennium Pharmaceuticals, Inc.
-
Patent number: 10335494Abstract: The present invention relates to methods for the treatment of cancers. In particular, the invention provides methods for treatment of cancer by administering an Aurora kinase inhibitor in combination with an anti-CD30 antibody. The combined administration of the Aurora kinase inhibitor and anti-CD30 antibody can be simultaneous, separate, sequential or consecutive.Type: GrantFiled: December 8, 2014Date of Patent: July 2, 2019Assignee: Millennium Pharmaceuticals, Inc.Inventor: Ole Petter Veiby
-
Patent number: 10335410Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.Type: GrantFiled: March 16, 2018Date of Patent: July 2, 2019Assignee: Millennium Pharmaceuticals, Inc.Inventors: Matthew O. Duffey, Dylan England, Brian Scott Freeze, Zhigen Hu, Steven Langston, Charles McIntyre, Hirotake Mizutani, Koji Ono, He Xu
-
Patent number: 10323018Abstract: This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R4, Rq, o, RA, W and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease.Type: GrantFiled: January 20, 2016Date of Patent: June 18, 2019Assignee: Millennium Pharmaceuticals, Inc.Inventors: Brian Scott Freeze, Kenneth M. Gigstad, David A. Janowick, Hong Myung Lee, Zhan Shi, Francois Soucy, Stepan Vyskocil
-
Publication number: 20190117652Abstract: The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering a Raf inhibitor in combination with a taxane. The present disclosure relates to methods of treating a subject suffering from cancer, comprising administering to the subject: (i) a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and (ii) a taxane or a pharmaceutically acceptable salt thereof; the amount of the Raf kinase inhibitor and taxane or a pharmaceutically acceptable salt thereof is such that the combination thereof is therapeutically effective in the treatment of the cancer.Type: ApplicationFiled: December 22, 2015Publication date: April 25, 2019Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Viviana BOZON, Katherine M. GALVIN, Rachael L. BRAKE, Qunli XU, Karuppiah KANNAN
-
Patent number: 10213436Abstract: Disclosed are methods for the treatment of various cell proliferative disorders. Disclosed in particular are methods for treatment of various cell proliferative disorders by administering a selective inhibitor of Aurora A kinase in combination with taxane-based chemotherapy, such as paclitaxel or docetaxel.Type: GrantFiled: September 3, 2015Date of Patent: February 26, 2019Assignee: Millennium Pharmaceuticals, Inc.Inventors: Jeffrey A. Ecsedy, Wen Chyi Shyu, Arijit Chakravarty, Robert W. Kleinfield, Kha N. Le, Karthik Venkatakrishnan
-
Patent number: 10202373Abstract: The present invention provides a compound of formula I: wherein R1, X1, X2, R2, R3, R4, R5, n, and m are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.Type: GrantFiled: January 13, 2015Date of Patent: February 12, 2019Assignee: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, He Xu, Yingchun Ye
-
Patent number: 10202389Abstract: Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein Y is and W, Z, XY, RY1, RY2 and RY3 are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.Type: GrantFiled: September 8, 2017Date of Patent: February 12, 2019Assignee: Millennium Pharmaceuticals, Inc.Inventors: Roushan Afroze, Indu T. Bharathan, Jeffrey P. Ciavarri, Paul E. Fleming, Jeffrey L. Gaulin, Mario Girard, Steven P. Langston, Francois Soucy, Tzu-Tshin Wong, Yingchun Ye
-
Publication number: 20190038762Abstract: This invention relates to antibody-drug conjugates capable of delivering cytotoxic compounds to cancers expressing the guanylyl cyclase C (GCC) transmembrane cell surface receptor.Type: ApplicationFiled: February 3, 2017Publication date: February 7, 2019Applicants: MILLENNIUM PHARMACEUTICALS, INC., IMMUNOGEN, INC.Inventors: Ole Petter VEIBY, Ravi V. J. CHARI, John M. LAMBERT, Katharine C. LAI, Robert W. HERBST, Scott A. HILDERBRAND
-
Patent number: 10179124Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.Type: GrantFiled: March 22, 2017Date of Patent: January 15, 2019Assignee: Millennium Pharmaceuticals, Inc.Inventors: Bing-Yan Zhu, Wenrong Huang
-
Publication number: 20180355062Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: July 6, 2018Publication date: December 13, 2018Applicants: Millennium Pharmaceuticals, Inc., Amgen British Columbia Inc.Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
-
Publication number: 20180346578Abstract: Antibody formulations are described comprising a mixture of an anti-a4b7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-a4b7 antibody in vivo.Type: ApplicationFiled: June 15, 2018Publication date: December 6, 2018Applicant: Millennium Pharmaceuticals, Inc.Inventors: Willow Diluzio, Phuong M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown, Irving H. Fox, Catherine Scholz, Erica Helen Jenkins, Maria Rosario
-
Patent number: 10143752Abstract: Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: GrantFiled: July 20, 2016Date of Patent: December 4, 2018Assignee: Millennium Pharmaceuticals, Inc.Inventors: Irving H. Fox, Catherine Scholz
-
Patent number: 10144742Abstract: This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.Type: GrantFiled: April 17, 2015Date of Patent: December 4, 2018Assignee: Millennium Pharmaceuticals, Inc.Inventors: Kenneth M. Gigstad, David P. Cardin, Takaharu Hirayama, Masaaki Hirose, Yongbo Hu, Hiroyuki Kakei, Hong Myung Lee, Takashi Motoyaji, Noriyuki Nii, Zhan Shi, Stepan Vyskocil, Hiroyuki Watanabe
-
Publication number: 20180327497Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: May 18, 2018Publication date: November 15, 2018Applicant: Millennium Pharmaceuticals, Inc.Inventors: Willow Diluzio, Phuong M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown, Irving H. Fox, Catherine Scholz, Erica Helen Jenkins, Maria Rosario
-
Publication number: 20180330043Abstract: The present invention provides methods for optimization of the harvest process by clarification of cell samples using centrifugation and depth filtration. The present invention provides methods for the determination of the optimal ratio of Q/? for the centrifugation step of a harvest process of a cell culture. The present invention provides methods for the determination of the number of particles and the size of the particles in the centrate of a centrifugation step of a harvest process of a cell culture by the use of imaging technology. The present invention provides methods for the scaling of the harvesting process from lab-bench scale to industrial scale.Type: ApplicationFiled: June 4, 2018Publication date: November 15, 2018Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Sheldon F. Oppenheim, Kevin C. Carrigan
-
Publication number: 20180311239Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.Type: ApplicationFiled: March 16, 2018Publication date: November 1, 2018Applicant: Millennium Pharmaceuticals, Inc.Inventors: Matthew O. DUFFEY, Dylan ENGLAND, Brian Scott FREEZE, Zhigen HU, Steven LANGSTON, Charles McINTYRE, Hirotake MIZUTANI, Koji ONO, He XU
-
Publication number: 20180289811Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: June 21, 2018Publication date: October 11, 2018Applicant: Millennium Pharmaceuticals, Inc.Inventors: Irving H. Fox, Catherine Scholz
-
Publication number: 20180290983Abstract: Disclosed are chemical entities which are inhibitors of Nedd8-activating enzyme (NAE), namely, the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate and pharmaceutically acceptable salts thereof; solid state forms thereof; and prodrugs thereof. Also disclosed are methods of using the chemical entities to treat disorders such as cancer.Type: ApplicationFiled: November 9, 2017Publication date: October 11, 2018Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ashley Sue MCCARRON, Todd B. SELLS, Matthew STIRLING, Stephen G. STROUD
-
Publication number: 20180271996Abstract: Disclose herein are combinations comprising HER2-targeted antibody-drug conjugates and immune checkpoint inhibitors and methods of using such combinations in a variety of therapeutic, diagnostic, and prophylactic indications.Type: ApplicationFiled: February 27, 2018Publication date: September 27, 2018Applicants: Mersana Therapeutics, Inc., Millennium Pharmaceuticals Inc.Inventors: Natalya D. BODYAK, Donald A. BERGSTROM, Marc HYER, Timothy B. LOWINGER, Marina PROTOPOPOVA, Ole Petter VEIBY, Aleksandr V. YURKOVETSKIY, Qing Xiu ZHANG
-
Publication number: 20180263979Abstract: The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering Raf inhibitors in combination with Aurora kinase inhibitors. The present disclosure relates to methods of treating subject suffering from cancer, comprising administering to the subject a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and an Aurora kinase inhibitor or a pharmaceutically acceptable salt thereof; the amount of said Raf kinase inhibitor or a pharmaceutically acceptable salt thereof being such that the combination thereof is therapeutically effective in the treatment of the cancer. In some [embodiments, the cancer is a solid tumor cancer.Type: ApplicationFiled: December 22, 2015Publication date: September 20, 2018Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Viviana BOZON, Katherine M. GALVIN